Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03495453
Recruitment Status : Recruiting
First Posted : April 12, 2018
Last Update Posted : July 1, 2020
Sponsor:
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
This single center prospective, randomized study will be conducted to investigate plaque removal and luminal gain using CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy System (OAS) (St.Paul, MN) versus Medtronic's Hawkone Directional Atherectomy system (DAS) (Minneapolis, MN) assessed by angiography and Intravascular Ultrasound (IVUS) in patients diagnosed with symptomatic obstructive femoro-popliteal disease will be analyzed. Both devices have received clearance by the Food and Drug Administration (FDA) for use by the label indication.Subjects will be randomized in a 1:1 fashion to receive treatment with either OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB) or DAS (using the Hawkone device) followed by DCB. Subjects in both arms will undergo IVUS before and after atherectomy, as well as at the conclusion of the procedure. Clinical data will be collected at baseline, immediately prior to the procedure, during and immediately after the procedures, and within 30 days, 6 and 12 months office visits after the procedure. Data may also be collected at office or hospital visits that are not scheduled but occur up to 12 months after the procedure, if they pertain to treatment related to the obstructive SFA disease. Data to be collected for this study includes demographics, medical history, procedural parameters and follow-up. The study will be conducted at one study center, 90 subjects will be enrolled in the trial with plan to accrue 60 subjects - 30 patients enrolled in the OAS arm and 30 patients enrolled in the DAS arm. The duration of the study is expected to be approximately 2 years from the date of first enrollment (1 year for enrollment of 60 subjects and a year for follow-up).

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease Device: Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS Device: Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound
Actual Study Start Date : March 20, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy (OAS)
OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB)
Device: Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device
HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.

Active Comparator: Medtronic's Hawkone Directional Atherectomy system (DAS)
DAS (using the Hawkone device) followed by DCB
Device: Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS
Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to "sand down" the buildup of material along the artery walls while leaving the healthy vessel behind.




Primary Outcome Measures :
  1. Measure of luminal area measured via Intravascular ultrasound (IVUS) at pretreatment and post atherectomy [ Time Frame: 12 Months ]

    All patients will undergo IVUS at

    • pre-treatment run to assess the severity and morphology of the plaque composition
    • post-atherectomy run to assess changes post atherectomy treatment


Secondary Outcome Measures :
  1. Plaque burden reduction. [ Time Frame: 12 Months ]
    Amount of removed plaque will be analyzed via IVUS pretreatment and post atherectomy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject's age ≥ 18 years;
  • Subject (or Legal Guardian if applicable) is willing and able to provide consent before any study-specific test or procedure is performed, signs the consent form, and agrees to attend all required follow-up visits.
  • Chronic, symptomatic lower limb ischemia defined as Rutherford categories 1-4
  • Target lesion(s) located in a superficial femoral or popliteal arteries
  • Degree of stenosis ≥70% via Qualitative Comparative Analysis (QCA)
  • Total Lesion Length ≥ 80 mm and ≤ 150 mm
  • Reference Vessel ≥ 3.0 mm and <6.5mm
  • Patent infrapopliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (<50% stenosis) to the ankle or foot with no planned intervention.
  • Subject is an acceptable candidate for percutaneous intervention using the OAS or DAS in accordance with their labeled indications and instructions for use

Exclusion Criteria:

  • Subjects who have an:
  • Previously stented target lesion/vessel.
  • Subjects who have undergone prior surgery of the SFA/PA in the target limb to treat atherosclerotic disease.
  • Presence of aneurysm in the target vessel.
  • Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.
  • Target vessel with moderate or severe angulation (e.g., > 30°) or tortuosity at the treatment segment, that precludes safe advancement of the atherectomy device.
  • Pre-planned interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than OAS or DAS.
  • Known hypersensitivity or contraindication to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated.
  • Known hypersensitivity/allergy to antiplatelet, anticoagulant, thrombolytic medications
  • Platelet count <80,000 mm3 or >600,000 mm3 or history of bleeding diathesis.
  • Patient has any known coagulation disorder, including hypercoagulability
  • Receiving dialysis or immunosuppressant therapy.
  • Patient has evidence of intracranial or gastrointestinal bleeding within last 3 months.
  • Patient has history of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within past 14 days,
  • Female patient who is pregnant or nursing a child,
  • Current participation in another investigational drug or device clinical study that has not completed the primary endpoint at the time of randomization/enrollment or that clinically interferes with the current study endpoints.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03495453


Contacts
Layout table for location contacts
Contact: Zulfiya Bakirova 212 263 5656 Zulfiya.Bakirova@nyumc.org

Locations
Layout table for location information
United States, New York
New York University School of Medicine Recruiting
New York, New York, United States, 10016
Contact: Zulfiya Bakirova    212-263-5656    Zulfiya.Bakirova@nyumc.org   
Principal Investigator: Anvar Babaev, MD         
Sponsors and Collaborators
NYU Langone Health
Investigators
Layout table for investigator information
Principal Investigator: Anvar Babaev NYU Langone Health
Layout table for additonal information
Responsible Party: NYU Langone Health
ClinicalTrials.gov Identifier: NCT03495453    
Other Study ID Numbers: 18-00005
First Posted: April 12, 2018    Key Record Dates
Last Update Posted: July 1, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases